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In a recent article in Molecular Systems Biology, Leroy Hood’s
group at The Institute for Systems Biology in Seattle and
George Carlson’s group at the McLaughlin Research Institute
in Great Falls, Montana, presented a comprehensively
annotated analysis of the initiation and progression of prion
disease in the mouse (Hwang et al, 2009). This paper is likely
to become a landmark in systems biology, both for its design
and speciﬁc methods and for its novel ﬁndings.
Since theemergenceof ‘omicstechnologies,’ globalanalyses
of gene expression (mRNA) and proteins have yielded
increasingly long lists of disease-associated molecules. Distin-
guishing true-positive from false-positive signals and organiz-
ing the ﬁndings into pathways, networks, and modules related
to histopathological and clinical phenotypes in temporal
and spatial dimensions is an overwhelming set of challenges.
The task is quadrupled by the complexity of the brain, the
peculiarities (if not mysteries) of the transmissible protein
agents of prion diseases, and the variability in both prion
properties and genetic make-up of infected organisms.
Remarkably, these problems were turned into levers to
enhance the studies by Hwang et al. With two prion strains,
characterized by different incubation times, and mice from six
different genetic backgrounds, including strains with altered
prion protein (PrP) expression levels, they set up a subtractive
analysis that drastically reduced biological and experimental
noise and focused on sets of genes reﬂecting the disease
process in common across the host genotypes and infectious
agent strains. They deﬁned the pathological/clinical end point as
‘disease incubation time’ from inoculation at age 5 weeks to
advanced clinical impairment, ranging from 56 to 392 days.
G e n o m e - w i d ea n a l y s i so fg e n ee x p r e s s i o ni nw h o l eb r a i n
homogenates was performed over 8–10 time points, with 1–4
weektimeintervalsadjustedtothewiderangeofincubationtimes.
From the massive amount of data accumulated, the authors
extracted a core of just 333 genes that were differentially
expressed in all ﬁve of the combinations involving mice with
normal levels of prion protein (compared with 7400 genes
differentially expressed in at least one of those ﬁve back-
grounds). These 333 genes are presented as central to prion
disease; 161 were mapped onto functional pathways using
protein–protein interaction, metabolic, and signaling pathway
informationfrompublicdatabases.Visualizationofchangesin
gene expression in critical biological modules functioning in
cellular and subcellular compartments over the months of
disease progression provides a dynamic scheme for the
processes that characterize the molecular conversion of
benign prion protein (PrP
C) to disease-causing PrP
Sc isoforms
accumulating in lipid rafts, followed by the three stages of
neuropathology: synaptic degeneration, activation of micro-
glia and astrocytes, and neuronal cell death.
There are many implications of this study. The same
principle of interaction of host and infectious agent variation
can be applied to eco-genetic systems analysis of other
infections (tuberculosis, malaria, HIV, inﬂuenza, Escherichia
coli, and so on). In fact, the concept can be generalized even
further by considering infectious agents as an example of
environmental and behavioral variable that act on genetic
variation to modify risk and manifestations of disease. From
the methodological point of view, the subtractive design
adopted by Hwang et al is a powerful strategy to reduce
biologicalandexperimental/technical noiseinlarge-scaledata
sets. Finally, the kinds of neuropathological responses appear
to be limited, so other degenerative disorders, including forms
of Alzheimer’s disease, may activate the same molecular and
cellular processes and express similar molecular signatures.
For example, there are clues from altered cholesterol,
sphingolipid, and glycosaminoglycan homeostasis that might
justify proposing statins and other drugs for the prevention of
both prion and Alzheimer’s disease.
The primary data (http://prion.systemsbiology.net) will be
a goldmine for secondary analyses by other researchers.
Notably, 178 genes not previously associated with prion
disease were identiﬁed among the 333 differentially-ex-
pressed, highly associated genes, including sets encoding
functional modules for androgen, iron, and arachidonate/
prostaglandin metabolism.
There are also limitations. Functional validation of the roles
of speciﬁc genes and of identiﬁed modules in the deﬁnable
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RT–PCR. At the system level, it will be interesting to
investigate the functional and pathophysiological conse-
quences of the dynamical changes in network architecture
observed by the authors. They recognize that this study
examined only the transcriptome. Epigenomics and miRNA
analysis will inform gene regulation, and proteomics and
metabolomics will conﬁrm and reveal new downstream
effector pathways and molecular targets for therapeutic and
preventive interventions. Relevant regions of the brain could
be compared, especially the thalamus where prion replication
seems to start. Validation of the mouse model also must
overcome a large experience that animal models are often
quite different from the human disease.
An area for future research is the creation of mathematical
models to describe the process and predict the dynamical
behaviorofgenes,mRNAs,miRNAs,proteins,andmetabolites
in the disease process. Both approximate and rigorous
modeling could be helpful in generalizing and predicting
results. Qualitative applied mathematical methods are gen-
erally limited to three nonlinear differential equations, which
are insufﬁcient to characterize these complex systems; global
sensitivity analysis, switching from mathematical to numeri-
cal analysis, should be more effective (S Schnell, personal
communication; e.g. Chen et al, 2009). Determination of the
kinetic parameters governing each step in prion activation and
progression of disease would promote modeling of temporal
and spatial dynamics (Kholodenko, 2006), whereas biochem-
ical pathways can be reconstructed using mass action time
series data fromperturbed systems(Srividhya et al, 2007). The
resulting networks can be queried for alignment, integration,
and evolution (Sharon and Ideker, 2006). In this regard, tools
such as those hosted at The National Center for Integrative
Biomedical Informatics (http://ncibi.org) will be quite useful.
In sum, the Hwang et al data set provides a valuable resource
to apply such approaches in mammalian systems.
Future prion disease research will generate molecular
explanations at the level of 3D structures, chemical modiﬁca-
tions, and patterns of misfolding for the distinct strains of
infectious prions with differences in sites of infection in the
brain, duration of incubation, and other properties governing
interactions with the host. At the practical level, brain-speciﬁc
plasma markers for the core processes discovered here could
become assays for testing asymptomatic cattle and people for
prion infections.
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